164 related articles for article (PubMed ID: 24038066)
1. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.
Moulis G; Sailler L; Sommet A; Lapeyre-Mestre M; Derumeaux H; Adoue D
Am J Hematol; 2014 Jan; 89(1):41-6. PubMed ID: 24038066
[TBL] [Abstract][Full Text] [Related]
2. Reemergence of Splenectomy for ITP Second-line Treatment?
Chater C; Terriou L; Duhamel A; Launay D; Chambon JP; Pruvot FR; Rogosnitzky M; Zerbib P
Ann Surg; 2016 Nov; 264(5):772-777. PubMed ID: 27741009
[TBL] [Abstract][Full Text] [Related]
3. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.
Auger S; Duny Y; Rossi JF; Quittet P
Br J Haematol; 2012 Aug; 158(3):386-98. PubMed ID: 22612239
[TBL] [Abstract][Full Text] [Related]
4. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.
Moulis G; Lapeyre-Mestre M; Mahévas M; Montastruc JL; Sailler L
Am J Hematol; 2015 Apr; 90(4):301-5. PubMed ID: 25557586
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
[TBL] [Abstract][Full Text] [Related]
6. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
8. [Treatment outcome of immune thrombocytopenia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2012 Oct; 153(41):1613-21. PubMed ID: 23045311
[TBL] [Abstract][Full Text] [Related]
9. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
Cooper N; Evangelista ML; Amadori S; Stasi R
Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
11. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
[TBL] [Abstract][Full Text] [Related]
13. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses.
Kumar S; Diehn FE; Gertz MA; Tefferi A
Ann Hematol; 2002 Jun; 81(6):312-9. PubMed ID: 12107560
[TBL] [Abstract][Full Text] [Related]
14. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years.
Palandri F; Polverelli N; Sollazzo D; Romano M; Catani L; Cavo M; Vianelli N
Am J Hematol; 2016 Jun; 91(4):E267-72. PubMed ID: 26799593
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.
Vianelli N; Galli M; de Vivo A; Intermesoli T; Giannini B; Mazzucconi MG; Barbui T; Tura S; Baccaranion M;
Haematologica; 2005 Jan; 90(1):72-7. PubMed ID: 15642672
[TBL] [Abstract][Full Text] [Related]
16. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.
Al Askar AS; Shaheen NA; Al Zahrani M; Al Otaibi MG; Al Qahtani BS; Ahmed F; Al Zughaibi M; Kamran I; Mendoza MA; Khan A
Int J Hematol; 2018 Jan; 107(1):69-74. PubMed ID: 28895035
[TBL] [Abstract][Full Text] [Related]
17. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R
Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
[TBL] [Abstract][Full Text] [Related]
18. Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.
Reboursiere E; Fouques H; Maigne G; Johnson H; Chantepie S; Gac AC; Reman O; Macro M; Benabed K; Troussard X; Damaj G; Cheze S
Int J Hematol; 2016 Jul; 104(1):85-91. PubMed ID: 27040278
[TBL] [Abstract][Full Text] [Related]
19. ITP and international guidelines: what do we know, what do we need?
Rodeghiero F; Ruggeri M
Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura.
Vancine-Califani SM; De Paula EV; Ozelo MC; Orsi FL; Fabri DR; Annichino-Bizzacchi JM
Platelets; 2008 Nov; 19(7):489-95. PubMed ID: 18979360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]